Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States

Venetoclax is a BCL2 inhibitor approved for 17p-deleted relapsed/refractory chronic lymphocytic leukemia with activity following kinase inhibitors. We conducted a multicenter retrospective cohort analysis of patients with chronic lymphocytic leukemia treated with venetoclax to describe outcomes, tox...

Descripción completa

Detalles Bibliográficos
Autores principales: Mato, Anthony R., Thompson, Meghan, Allan, John N., Brander, Danielle M., Pagel, John M., Ujjani, Chaitra S., Hill, Brian T., Lamanna, Nicole, Lansigan, Frederick, Jacobs, Ryan, Shadman, Mazyar, Skarbnik, Alan P., Pu, Jeffrey J., Barr, Paul M., Sehgal, Alison R., Cheson, Bruce D., Zent, Clive S., Tuncer, Hande H., Schuster, Stephen J., Pickens, Peter V., Shah, Nirav N., Goy, Andre, Winter, Allison M., Garcia, Christine, Kennard, Kaitlin, Isaac, Krista, Dorsey, Colleen, Gashonia, Lisa M., Singavi, Arun K., Roeker, Lindsey E., Zelenetz, Andrew, Williams, Annalynn, Howlett, Christina, Weissbrot, Hanna, Ali, Naveed, Khajavian, Sirin, Sitlinger, Andrea, Tranchito, Eve, Rhodes, Joanna, Felsenfeld, Joshua, Bailey, Neil, Patel, Bhavisha, Burns, Timothy F., Yacur, Melissa, Malhotra, Mansi, Svoboda, Jakub, Furman, Richard R., Nabhan, Chadi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6119152/
https://www.ncbi.nlm.nih.gov/pubmed/29880613
http://dx.doi.org/10.3324/haematol.2018.193615

Ejemplares similares

Ejemplares similares